MET and lung carcinoma: In fact, in prospective clinical trials, tepotinib, capmatinib, and savolitinib showed high activity in advanced stage lung cancer patients harboring the MET exon 14 skipping mutation, including treatment-naïve patients and those affected by pulmonary sarcomatoid carcinoma [13,20].